Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

Review of the EMPEROR-Reduced RCT (n=3,730) found that the reduction of risk for hospitalisation for heart failure from the use of empagliflozin was not impaired in intensively treated patients who were receiving sacubitril/valsartan vs those not on this treatment

European Heart Journal